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TOK-001Cytochrome P450 17A1 (CYP17A1) is associated in the steroid hormone biosynthesis in human. As cell prolifer-
ation of prostate cancer in response to androgen steroid, an inhibition of CYP17A1 becomes an alternative ap-
proach to inhibit biosynthesis of androgen and support treatment of prostate cancer.
However, biology-driven inhibitor development of prostate cancer is poorly elucidated. The aims of this study are
to address structural differences at atomic-level between CYP17A1 and inhibitors i.e., abiraterone and TOK-001,
and further investigate the effect of point mutation of CYP17A1 on the active site stability and the local interac-
tions that are hydrophobic interaction and hydrogen bonding throughout molecular dynamics (MD) simulation.
After performingmultiple comparisons among four different complexes across CYP17A1 and inhibitors, interest-
ingly TOK-001 oriented toward the active pocket and formed larger volume with I-helix of CYP17A1 than
abiraterone, whereas abiraterone showed tighter binding andmore active site stability. Considering on the effect
of hydrophobic interaction and hydrogen bonding between abiraterone and CYP17A1, the key residues of
Phe114, Ile371, Val482, and Asn202 were identiﬁed. This contributes into tight binding interactions; however
abiraterone is effectively weakened along with the global conformation mobility increased in A105L mutation.
Surprisingly, overall conformation of the CYP17A1 remained stable when bound to TOK-001. This basic knowl-
edge can guide future experiments on design of efﬁcient inhibitors for CYP17A1, which provides theoretical
basis of androgen-dependent disease therapy.
© 2015 Xiao et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural
Biotechnology. This is an open access article under the CCBY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Cytochrome P450 17A1 (CYP17A1, P450c17) is a crucial enzyme
which belongs to the cytochrome P450, family 17, subfamily A. It is a
dual-functionmonooxygenasewhich plays role in steroid hormonebio-
synthesis in humans [1]. Currently, CYP17A1 is a target of interest for
the treatment of breast and prostate cancer cells that proliferate in re-
sponse to androgen and estrogen steroids [2,3]. So far, there are many
studies focusing on mutation in CYP17A1 for structural and functional
analysis [4–12]. Most of studies are often targeted at position of 105
from alanine to leucine in CYP17A1 active site (A105L mutation)
which results in enzyme activities changes [13–15]. Consequently, this
A105L mutation resulted in inﬂuencing the androgen level, thus sup-
posed to be contributed into the androgen-dependent prostate cancer
development. Several years ago, inhibitors of CYP17A1 were designed
without structural information which was supposed to bind the cyto-
chrome P450 haem iron [16]. Nonetheless, it has been hampered to re-
veal fundamental structural features for effective CYP17A1 inhibition.ipa.v@ku.ac.th
n behalf of the Research Network of CRecently, DeVore and Scott presented binding structures and modes of
CYP17A1, in the presence of either abiraterone or TOK-001 [17]. This re-
port showed better understanding of the CYP17A1 catalyticmechanism.
In brief, abiraterone acetate (abiraterone), it is an active form of USFD-
approved prodrug of this CYP17A1 inhibitor which improves overall
survival in men with metastatic castration-resistant prostate cancer
(CRPC), including patients for whom the disease has been progressed
following chemotherapy, with compounds, such as docetaxel and the
androgen receptor blocker enzalutamide [18–20]. Abiraterone binds to
the CYP17A1 haem iron active site [17]with high afﬁnity for prevention
of androgen production. Using this full inhibitor, however, it induces the
steroid imbalance of human, and thus frequently leads to hypertension,
hypokalemia, and adrenocortical insufﬁciency, which are required to be
monitored and be treated with additional drugs [21]. Furthermore,
there is a report that the full inhibition of CYP17A1 by abiraterone pos-
sibly allows the androgen precursors ﬂow through a “backdoor” andro-
gen biosynthesis pathway [22]. This provides a probable route that can
permit cancer progression.
Concerning on TOK-001 (also called as β-(hydroxy)-17-(1H-benz-
imidazole-1-yl) androsta-5, 16-diene, galeterone, or VN/124-1), it is
identiﬁed as a selective development of drug candidate which modu-
lates multiple targets in the androgen receptor (AR) signaling pathwayomputational and Structural Biotechnology. This is an open access article under the CC BY
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identiﬁed as the ﬁrst example of an anti-hormonal agent which is an in-
hibitor of androgen synthesis [24–27]. Because of its impressive anti-
cancer properties, TOK-001 was selected as a clinical candidate, and it
is currently undergoing phase III clinical trials for CRPC. Notably, TOK-
001 is both a CYP17A1 inhibitor and AR antagonist [25] and the similar-
ity of these binding modes is probably the reason for this dual mecha-
nism of action.
However, the different bindingmechanism of prostate cancer inhib-
itors of abiraterone and TOK-001with CYP17A1 in terms of atomic-level
structural characterization is still poorly elucidated. The aims of this
study are therefore to address structural differences at atomic-level be-
tween CYP17A1 and inhibitors i.e., abiraterone and TOK-001, and fur-
ther investigate the effects of point mutation of CYP17A1 on local
interactions that are hydrophobic interaction and hydrogen bonding
between these two inhibitors throughout molecular dynamics (MD)
simulation.
To explore, we initially collected three available complex structures
of CYP17A1 and inhibitors, i.e., two complexes for abirateronewithwild
type (WT) and mutant (MT) CYP17A1 and one complex for TOK-001
with WT CYP17A1. We then constructed additional complex for TOK-
001 with MT CYP17A1. MD simulations were performed on these four
complexes to analyze the stability of an individual complex. Multiple
comparisons of these complexes were afterwards analyzed on active
site stability of the enzyme, local interactions, i.e., hydrophobic interac-
tion and hydrogen bonding. This basic knowledge of inhibitor binding
characteristics and key residues contributions leads to better under-
standing on cytochrome P450 superfamily enzymes, so that desirableFig. 1. Overview of MD simulation method used for comparative analysis between prostate can
two steps, namely, data collection and model construction (A) and MD simulation (B).changes in their enzymatic activitiesmay be achieved. This can guide fu-
ture computational and experimental work on efﬁcient inhibitor design
for CYP17A1 in theoretical basis of androgen-dependent disease
therapy.
2. Materials and Methods
An overview of the approach employed here for comparative analy-
sis between prostate cancer inhibitors abiraterone andTOK-001 binding
with CYP17A1 throughoutMD simulation is depicted in Fig. 1. It is divid-
ed into two sections: 1) data collection and model construction, and
2) MD simulation. In this study, three complexes were retrieved from
database that include a complex of abiraterone binding with WT
CYP17A1 (AER), a complex of abiraterone binding with MT CYP17A1
(AERm), and a complex of TOK-001 binding with WT CYP17A1 (TOK).
For additional complex of TOK-001 binding with MT CYP17A1
(TOKm), it was constructed throughout this study as described in the
following.
2.1. Data Collection and Model Construction
As shown in Fig. 1A, the initial structures for AER, TOK, and AERm
were retrieved from Research Collaboratory for Structural Bioinformat-
ics, the Protein Data Bank (RCSB PDB) (www.rcsb.org/pdb/) (PDB ID
code: 3RUK [17], 3SWZ [17], and 4NKV [15], respectively). It is noted
that AERm has point mutation at position of 105 of CYP17A1 changing
from alanine to leucine (A105L mutant). For TOKm, it was constructed
through Swiss-PdbViewer [28] based on the X-ray structure of TOKcer inhibitors abiraterone and TOK-001 binding with CYP17A1. Illustration is divided into
522 F. Xiao et al. / Computational and Structural Biotechnology Journal 13 (2015) 520–527and then CYP17A1 was mutated to obtain A105L mutant. The mutation
of A105L was selected according to the key position in active site of
CYP17A1 through the side chain interacting with inhibitors, which led
to CYP17A1 functional deﬁciency. Concerning to all of these four com-
plexes, only one monomer structure of enzyme and inhibitor were
retained and prepared without haem. Hydrogen atoms were subse-
quently added to the initial structures with Chimera 1.10.1 [29]. The
force ﬁeld parameters of abiraterone and TOK-001 were supplied by
GROMOS54A7 with Automated Topology Builder (ATB) and Repository
2.0 webserver [30].
2.2. MD Simulation
To obtain inhibitor and enzyme binding diversities at atomic level
and the effects induced by a minor conformational change of the en-
zyme, MD simulation was carried out using GROMACS version 4.6.5
[31] with the standard of GROMOS96 force ﬁeld parameter set 43a2
[32]. The procedure of ourMD simulation is shown in Fig. 1B. First, initial
structural complexeswere solvated in a rectangularwater boxwith sin-
gle point charge water model [33] and were neutralized with chloride
ions. To eliminate any unfavorable contacts, energy minimization was
performed. Each complexwasﬁrstminimizedwith the steepest descent
algorithmby5000 steps followedwith L-BFGS algorithm [34,35]. Subse-
quently, the minimized systems through MD run were simulated for
50 ns keeping temperature at 300 K and the pressure at 1 bar which
maintained by Berendsen temperature and pressure coupling method
[36]. LINCS algorithm [37] was obtained to constrain the hydrogen-
contained bonds, and the Particle-Mesh Ewald (PME) [38] method
was used to calculate the electrostatic interactions. To the end, the MD
simulation trajectories were analyzed at the equilibrium state using
the tools provided by GROMACS and the scripts written in this study.
For illustration, PyMOL [39] and Chimera [29] were used.
3. Results and Discussion
The overall structures and active sites of WT CYP17A1 bound to
abiraterone (AER) and TOK-001 (TOK) were relatively conserved ac-
cording to the X-ray structures, as shown in Fig. 2. These complex struc-
tures demonstrated the characteristics of cytochrome P450 fold
and inhibitor binding mode. In details, the α-face packed against theFig. 2.A colored representation of the CYP17A1-abiraterone/TOK-001 structure, Rainbow cartoo
TOK-001 are represented with purple and cyan sticks, respectively. Right box indicates the shaI-Helix and formed a highly complementary hydrophobic planer surface
with Gly301 and Ala302, while the β-face was primarily lined with hy-
drophobic atomsof Ala105, Ala113, Phe114, Ile206, Leu209, Val236, and
Val482 (see Fig. 2). To gain insight into the bindingmode and the inﬂu-
ence of the position of 105 pointmutation on the CYP17A1 bindingwith
inhibitors, MT CYP17A1 bound to abiraterone (AERm) and TOK-001
(TOKm) were then studied and performed on MD simulation. So far,
an application of MD simulation method has become indispensable in
computational area with regards to enzyme and inhibitor interactions
and enzyme conformation changes [40,41]. In subsequent sections,
the constructed model of TOKm is initially presented and the structural
stability among four complexes (AER, AERm, TOK, and TOKm) and their
multiple comparisons on active site stability, hydrophobic interaction,
and hydrogen boding are later discussed.
3.1. Assessment of the Constructed Model of TOKm
To assess the constructed model of TOKm, the TOK-001 remained
the unsubstituted α-face against the I-Helix, and the β-face toward
the active pocket characterized by residues Leu105, Ala113, Phe114,
Asn202, Ile205, Ile206, Leu209, Leu214, Arg239, Asp298, Ala302,
Thr306, Ile371, and Cys442 of CYP17A1. The major difference between
TOK and TOKm was the bulk in the active site caused by substitution
of leucine from alanine. This reduction in active site volume induced
by Leu105 from alanine in TOKm did not alter the orientation of TOK-
001 or any of its initial interaction with the CYP17A1 active site in
TOKm complex. In this structure, the impact of the A105L mutation
thus appears to be only steric in nature, as presented in abiraterone
binding complex [15].
3.2. Stability of the AER, AERm, TOK, and TOKm during MD Simulation
During 50 ns of MD simulation, the root mean square deviation
(RMSD) of all Cα atoms for four complexes (AER, AERm, TOK, and
TOKm) were calculated to provide an overall measure of the departure
of the structures from the initial coordinates as shown in Fig. 3. It is clear
that the RMSDvalues are convergent and the systems remain in equilib-
riumduring the 10–50 ns for AER, AERm, and TOK,while this value ﬂuc-
tuates until 13 ns for TOKm (see Fig. 3). With these regards, the results
demonstrated that the global structures of four enzymes are relativelyn of CYP17A1 colored from theN-terminus (blue) to the C-terminus (red), abiraterone and
red active site of abiraterone and TOK-001.
Fig. 3. The RMSD values of Ca atoms versus simulation time on four different complexes
(AER, AERm, TOK, and TOKm).
Table 1
Thepercentages of four complexes across two local interaction types of hydrophobic inter-




Resid AER AERm TOK TOKm
Hydrophobic interaction C18 102 0.00 0.00 25.72 0.00
113 0.14 8.22 2.18 17.38
114 43.18 5.42 15.48 9.12
214 0.04 72.68 22.28 40.66
367 0.14 27.16 0.12 44.14
371 52.82 25.46 10.62 4.62
482 63.40 4.60 17.14 9.90
483 0.22 2.72 0.00 12.68
C19 105 0.16 51.56 67.00 16.92
114 42.24 0.02 0.02 0.50
205 23.42 5.56 18.72 17.16
206 29.74 3.38 18.40 9.72
209 3.74 0.88 73.90 2.14
214 0.00 9.50 0.00 10.12
482 32.12 81.64 21.22 90.54
483 0.00 3.64 0.00 43.06
Hydrogen bonding O3 202 70.06 18.16 32.26 0.00
Note: Resid stands for “Residue Id number.”
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tional characteristic analysis of AER, AERm, TOK, and TOKm were per-
formed on the last 37 ns of the simulation trajectories. Over the 50 ns
trajectory, the RMSD for the abiraterone binding complexes continued
to raise to a value around 3.55 Å (AER) and 3.27 Å (AERm) relative to
the crystal structures, respectively, while those of the TOK-001 binding
complexeswere leveled around 4.00 Å. During the last 37 ns simulation,
the Cα atoms RMSD values for all four enzymes stayed fairly low with
the average RMSD values of 3.55 Å (standard deviation (SD): 0.11 Å),
3.27 Å (SD: 0.16 Å), 4.00 Å (SD: 0.20 Å), and 4.00 Å (SD: 0.15 Å) for
AER, AERm, TOK, and TOKm, respectively. Most notably, the time evolu-
tion of the RMSD values in Fig. 3 indicates that the enzyme ﬂexibility
was signiﬁcantly affected by A105Lmutation of CYP17A1 in abiraterone
binding systems, while it is not distinct in TOK-001 binding systems. To
extend this analysis, the root mean square ﬂuctuation (RMSF) values of
Cα atoms calculation were also performed for MD simulation. The re-
sults suggest that the A105L mutation indeed induced some changes
in RMSF variation in many regions as shown in Fig. A.1.
3.3. Multiple Comparisons among AER, AERm, TOK, and TOKm
Analysis of time-dependent atomic motion via MD simulation pro-
vides an effective means of exploring further inhibitor and enzyme in-
teractions that are difﬁcult to obtain from static structures alone, such
as the crystal structures or the results of docking studies. In order to ad-
dress structural differences at atomic-level between CYP17A1 and in-
hibitors i.e., abiraterone and TOK-001, and further investigate the
effect of point mutation of CYP17A1 on the active site stability, and
local interactions, namely, hydrophobic interaction, and hydrogen
bonding across these four complexes (AER, AERm, TOK and TOKm)
throughout MD simulation as described below.
3.4. Active Site Stability
In order to characterize the effect of the A105L mutation upon con-
formational enzyme change of CYP17A1, here we used the RMSF analy-
sis, which is capable of monitoring the local motion in the enzyme
structure. Fig. A.2 shows the RMSF of Cα of binding site residues of the
WT and MT CYP17A1 over 50 ns in a simulation run. As evidence from
Fig. A.2, it is clear that A105L altered the binding site ﬂexibility when
compared to the WT, but the trends of mobility change of residues for
those located in the active site are not entirely consistent. Residues for
those located nearAla/Leu105, such as 205–214, 482, and 483, theirmo-
bility increases much according to the A105L mutation, while the other
residues stay almost the sameor declinewhen compared to theWT sys-
tem. The reasonable explanation is a hydrophobic interaction network
formed by residues 105, 205, 206, 209, 482, and 483 (Fig. A.3) in the
WT system. The A105L mutation introduces interference to the existed
network through the side chain of Leu105 involved in the network.While the other active site residues in AERm are not affected distinctly
by thismutation, the effect caused by A105Lmutation in TOK-001 bind-
ing system is more obvious than in abiraterone binding system as
shown in Fig. A.2. The possible explanation is that abiraterone binds to
the CYP17A1 more tightly than TOK-001, thus the residues for those
interacted with abiraterone are more rigid than TOK-001.
3.4.1. Local Interactions
Although the global structureswere conserved betweenWT andMT
CYP17A1, the local structural features are quite distinctive. The α-face
positioned against the I-Helix, while the β-face of the steroidal ring,
which included C18 and C19methyl groups, interacts with hydrophobic
residues around the binding site. Table 1 lists the crucial residues that
made a large contribution to the inhibitor binding afﬁnity for all four
complexes. Several hydrophobic residues, such as Leu102, Ala/Leu105,
Ala113, Phe114, Ala113, Ile206, Leu209, Leu214, Ala367, Ile371,
Val482, and Val483, as well as the hydrophilic residue Asn202 were in-
volved in the active pocket, and they also made a large contribution to
the inhibitor binding. When the representative structures of these four
complexes were superimposed with each other to obtain the prelimi-
nary estimation of the effect of mutation over the conformational
change of the enzyme and inhibitor binding, this may suggest a molec-
ular mechanism underlying the heterogeneities in conformational en-
zymes. The results are shown in Fig. 4.
3.4.2. Hydrophobic Interaction
Hydrophobic is one of local interactions type. Since the active site of
abiraterone and TOK-001 binding in CYP17A1 is mainly hydrophobic,
the main contributions of inhibitors binding to CYP17A1 enzyme are
the hydrophobic interactions formed between inhibitors and the active
site non-polar residues. To investigate the differences between
abiraterone/TOK-001 and CYP17A1, hydrophobic interactions of four
complexes were analyzed in details. We ﬁrst investigated the effect
caused by A105L mutation to abiraterone binding. As shown in Fig. 4A
and Table 1, when the representative structures of AER are compared
with AERm, it is observed that the orientation of abiraterone remains
the same in two complexes, whereas interactions and contributions be-
tween inhibitor and enzyme are distinct. The abiraterone forms stron-
ger hydrophobic interactions with Phe114, Ile205 Ile206, Leu209,
Ile371, and Val482 of WT CYP17A1 in AER, while most of those strong
interactions reduced in AERm. The hydrophobic interactions between
abiraterone and Leu105, Ala113, Leu214, Ala367, and Val483 of MT
CYP17A1 mainly contributed into the inhibitor binding in AERm com-
plex. In addition, the overall interactions contributing to inhibitor
Fig. 4. Illustration shows all pairwise complex structures comparisons of abiraterone and TOK-001 bound to WT and MT CYP17A1. (A) AER and AERm, (B) TOK and TOKm, (C) AER and
TOK, (D) AERm and TOKm. CYP17A1 is representedwith colored cartoonwhile inhibitors and active site residues from TOK (cyan), TOKm (green), AER (magenta), and AERm (yellow) are
represented with colored stick.
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presence of the bulk side chain, this residue extends its side chains to
the space of existed hydrophobic interaction network as shown in
Fig. A.3, leading to a series of successive movement of the hydrophobic
residues that interact with abiraterone in MT CYP17A1, including
Ala113, Ile206, and Leu209. Thus, the presence of the bulk side chain
of Leu105 was not only to reduce the active site volume [15] but also
to introduce the disruption of the hydrophobic interaction network.
From the values of RMSD (see Fig. 3), we could see that the A105L mu-
tation increased the global conformation stability of the enzyme; how-
ever it decreased the inhibitor and enzyme interactions.
By comparing of TOK and TOKm (Fig. 4B), we could see the hydro-
phobic interactions formed by TOK-001 and Leu102, Ala105, Phe114,
Ile206, and Leu209 of WT CYP17A1, those mainly contributed into the
inhibitor binding which were disappeared or weakened, whereas the
interactions between TOK-001 and Ala113, Leu214, Ala367, Val482
andVal483 ofMTCYP17A1were strengthened in TOKm. The overall hy-
drophobic interactions contributing in TOKm were not altered accord-
ing to the mutation. In addition to the variation of RMSD values of
TOK and TOKm, we could conclude that the A105L mutation did not
alter the binding of TOK-001 to CYP17A1 and the native conformation
mobility of the enzyme distinctly.
To investigate the differences of these two inhibitors bound to WT
CYP17A1, the comparisons of AER and TOK complexes are shown in
Fig. 4C. In contrast to abiraterone, TOK-001 moved toward the hydro-
phobic pocket and formed a slightly larger volume between TOK-001
and I-helix, and the interactions between inhibitor and enzyme were
distinct. In AER complex, Phe114, Ile206, Ile371, and Val482 of
CYP17A1 formed hydrophobic interactions with abiraterone and made
important contributions to abiraterone binding. Whereas, a distinct in-
teraction network was detected in TOK, and Leu102, Ala105, Leu209,
and Leu214 of CYP171 were involved. In addition, the RMSD value of
AER of 3.55 (SD: 0.11 Å) was much lower than TOK of 4.00 Å (SD:
0.20 Å), and the overall hydrophobic interactions between the inhibitor
and enzyme in AER were much stronger than TOK. These achievedresults are consistent with the in vitro studies presented by Jacoby and
Williams [42]. Their studies showed that TOK-001 activity could inhibit
human CYP17A1, demonstrating the 17, 20-lyase (IC50= 23 nmol l−1)
versus 17α-hydroxylase (IC50= 73 nmol l−1). In contrast, abiraterone
activity showed more potent for CYP17A inhibition demonstrating 17,
20-lyase (IC50 = 12 nmol l−1) and 17α-hydroxylase (IC50 =
7 nmol l−1) [42].
In order to ﬁnd out the differences between two inhibitors bound to
MT CYP17A1, we superimposed the AERm and TOKm and made com-
parisons (Fig. 4D). In contrast to the large difference in binding be-
tween the two inhibitors bound to WT CYP17A1, abiraterone and
TOK-001 showed similar overall interactions and contributions in MT
complexes. Themain contribution of hydrophobic interactions between
abiraterone and Leu105, Leu214, and Ile371 ofMT CYP17A1 in AERm al-
most equal to the interactions formed by TOK-001 and Ala113, Phe114,
Ile205, Ile206, Ile209, Ala367, Val482, and Val483 of MT CYP17A1 in
TOKm. In these two complexes, the inhibitors and binding site residues
showed similar structural migrations.
3.4.3. Hydrogen Bonding
Hydrogen bonding always plays an important role in inhibitor and
enzyme binding. It is also the other type of local interactions. It would
be ideal for the polar residues to have both hydrogen bonding and fa-
vorable packing interaction with the neighboring residues. Here, the
single direct hydrogen bonding between inhibitor and the enzyme is
part of a larger hydrogen bonding network. In all four complexes, this
hydrogen bonding network involves Arg239, Tyr201, Asn202, inhibi-
tors, and several conserved water molecules, as shown in Fig. 5. The
only direct intermolecular hydrogen bonding, between the 3β-
hydroxyl group of inhibitors and Asn202, is presented in all complexes
except TOKm. The hydrogen bonding (acceptor H-donor atomdistances
of b3.5 Å and acceptor . . . H-donor angles of b60°) was reported when
the occupancy was calculated of the percentage of time during simula-
tion that the hydrogen bonding existed. Asn202 has important contri-
butions to inhibitor binding through the formation of hydrogen
Fig. 5. Illustration shows hydrogen bonding formed between CYP17A1 and inhibitor. Hydrogen bonding network of abiraterone bound to WT CYP17A1 at the top of the active site. Res-
idues of CYP17A1, inhibitor, and water molecule that involved in the hydrogen bonding network are represented with colored stick. Blue dashed line represents hydrogen bonding.
525F. Xiao et al. / Computational and Structural Biotechnology Journal 13 (2015) 520–527bonding in approximately 70.06%, 18.16%, and 32.26% frames for AER,
AERm, and TOK in the simulation trajectories, respectively, while this
hydrogen bonding was not detected in TOKm. We could see that, both
in abiraterone and TOK-001 binding complexes, this hydrogen bonding
was weakened according to the A105L mutation. The most possible ex-
planation is that the side chain of Leu105 introduces some disruption of
the hydrophobic interaction network, and meanwhile weakened the
hydrogen bonding. Further analysis on the representative structures of
the inhibitor-CYP17A1 complexes suggests that hydrogen bonding
may play an important role to stabilize the inhibitor binding. To investi-
gate the strength of hydrogen bonding in four complexes during MD
simulation, we further examined the hydrogen bonding distances be-
tween O3 of inhibitors and OD1 of Asn202 in the four complexes. This
distance value remains relatively stable around 3.19 Å (SD: 0.40 Å) in
AER; however, it ﬂuctuates in a wider range in AERm for 4.40 Å (SD:
1.0 Å) and TOK for 4.15 Å (SD: 1.27 Å). For the simulation in TOKm,
no hydrogen bonding was formed.Fig. A.1. The calculated RMSF variations of Cα atoms of AER (red line), AERm (blue line),
TOK (black line), and TOKm (green line).4. Conclusions
In conclusion, our study provides detailed atomistic insight into the
structural differences of abiraterone and TOK-001 binding to WT and
MT CYP17A1, as well as the effect on the inhibitors binding and confor-
mational changes upon the A105L mutations of CYP17A1 for both
abiraterone and TOK-001 binding. Considering multiple comparisons
among four different complexes toward focusing on active site stability,
interestingly in TOK complex, TOK-001 oriented toward the active
pocket and formed larger volume with I-helix of CYP17A1 than
abiraterone in AER complex. In contrast, AER complex showed tighter
binding and more stability than TOK complex. For the local interactions
between CYP17A1 and inhibitors, considering on hydrophobic interac-
tions between abiraterone and residues of Phe114, Ile371,Val482 of
CYP17A1 and the hydrogen bonding formed by O3 from abiraterone
and OD1 from residue of Asn202 of CYP17A1 mainly contributed to
the tighter binding than TOK-001.
Thismainly resulted in the difference of these two complexes, none-
theless, the local interactions between abiraterone and CYP17A1 in AER
complexweakened alongwith an increasing of the conformational mo-
bility according to the A105Lmutation. In comparison, the local interac-
tions in TOK complex were even weaker than AER complex withoutaffected distinctly by the A105Lmutation on the conformational mobil-
ity. This suggests that the overall conformation of the CYP17A1 remains
stable. This basic knowledge of inhibitor binding characteristics and key
residues contributions can guide future effort on cytochrome P450 su-
perfamily enzymes, so that desirable changes in their enzymatic activi-
ties may be achieved through changing an active site and/or an
allosteric site of an enzyme. Additionally, this present study provides
important insights into the effect of minor structural change on enzyme
binding to different inhibitors, which can guide future experimental on
efﬁcient inhibitors design for CYP17A1, which provides theoretical basis
of androgen-dependent disease therapy.Acknowledgement
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ig. A.3. Illustration shows hydrophobic interaction network. (A) Residues involved in the hydrophobic interaction network are representedwith colored surfacewhile abiraterone is rep-
esented with magenta stick. (B) 2D representation of the hydrophobic interaction network is presented.
Fig. A.2. The calculated RMSF variations of Cα atoms of active site residues of AER (red line), AERm (blue line), TOK (black line), and TOKm (green line).
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